COVID-19
Regístrese
metricas
covid
Enfermedades Infecciosas y Microbiología Clínica
Suscribe to the journal
Buscar en
Enfermedades Infecciosas y Microbiología Clínica
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica In vitro activity of ceftobiprole and dalbavancin against a collection of coagul...
Journal Information
Back to article

Statistics

Follow this link to access the full text of the article

Original article
In vitro activity of ceftobiprole and dalbavancin against a collection of coagulase-negative staphylococci isolates from clinical samples with reduced susceptibility to daptomycin and/or resistant to linezolid or glycopeptides
Evaluación de la actividad in vitro de ceftobiprol y dalbavancina frente a estafilococos coagulasa negativos con sensibilidad disminuida a daptomicina y/o resistentes a linezolid o glucopéptidos aislados de muestras clínicas
Silvia Velasco de la Fuentea,
Corresponding author
silviavefu@gmail.com

Corresponding author.
, Marta Fernández-Martineza, Jesús Rodríguez Lozanoa, Daniel Pablo-Marcosa, María Sillera, Jorge Calvo Montesa,b
a Microbiology Service, University Hospital Marqués de Valdecilla – IDIVAL, Santander, Spain
b CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Spain
Read
292
Times
was read the article
83
Total PDF
209
Total HTML
Share statistics
Article information
ISSN: 0213005X
Original language: English
DOI:10.1016/j.eimc.2022.06.011
The statistics are updated each day
Year/Month Html Pdf Total
2024 September 27 5 32
2024 August 29 4 33
2024 July 11 10 21
2024 June 15 3 18
2024 May 22 3 25
2024 April 2 0 2
2024 February 1 0 1
2024 January 2 0 2
2023 December 3 0 3
2023 November 97 37 134
2023 March 0 4 4
2023 January 0 3 3
2022 August 0 14 14
Show all

Follow this link to access the full text of the article

Subscribe to our newsletter

Publish in
Enfermedades Infecciosas y Microbiología Clínica
Free access articles
Uncommon lip lesions in an HIV...
10.1016/j.eimc.2024.06.017
Tolerance of Atovacuona/proguanil in off-label...
10.1016/j.eimc.2024.06.012


La Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica agradece la colaboración de:

SOCIOS PROTECTORES

    - Pfizer GEP, S.L.U.
    - Shionogi, S.L.U.
    - AbbVie Spain, S.L.U.
    - Gilead Sciences, S.L.U.
    - Vircell Spain, S.L.U.
    - Roche Diagnostics, S.L.U.
    - ASTRAZENECA FARMACÉUTICA SPAIN, S.A.
    - Qiagen Iberia S.L.
    - Laboratorios ViiV Healthcare, S.L.

SOCIOS PATROCINADORES

- Becton Dickinson S.A.U.
- Janssen-Cilag, S.A.
- Angelini Farmacéutica, S.A.
- Biomerieux España, S,A.U.
- Merck Sharp & Dohme de España, S.A.
- Hologic Iberia, S.L.U.
- Laboratorios Menarini S.A.
- Accelerate Diagnostics S.L.
- Abbott Laboratories, S.A.
- Cepheid Iberia S.L.U.
- Illumina Productos de España. S.L.U.
- DiaSorin Iberia, S.A.
- GlaxoSmithKline, S.A.
- Sysmex España S.L.

Enfermedades Infecciosas y Microbiología Clínica follows the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals

es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos